M199. COPY NUMBER VARIANCE (CNV) ANALYSIS TO DETERMINE OPTIMAL ANTIPSYCHOTIC DOSAGE IN SCHIZOPHRENIA: A PILOT STUDY

Background The relationship between genetic polymorphisms of antipsychotic drug-metabolizing agents and drug response has been thoroughly investigated and analyzed. However, from a pharmacokinetic standpoint, few studies have explored the relationship between Copy number variants (CNV) and antipsychotic dosage. The aim of the present study is to test the association between antipsychotic dosage and CNV in schizophrenia (SCZ) patients. Methods The current dosage of antipsychotic medications was collected from 263 schizophrenia patients. The dosage was standardized using three different methods: chlorpromazine equivalent(CPZe), defined daily dose (DDD), and percentage of maximum dose (PM %). The patients were then genotyped using the Illumina HumanOmni2.5–8 BeadChip Kit. Results The CNV analysis did not show that CNVs are associated with dosage variation for CPZe, PM %, and DDD. Discussion In this pilot sample, we investigated for the first time CNVs and standardized antipsychotic dosage. The relationship between CNV and optimal antipsychotic dosage has far reaching clinical implications. Further analysis is required that utilitze large prescription databases to build on the results presented in this pilot study.